Huang Jian-You, Shih Ping-Cheng, Chen Chu-Ting, Lin Han-Yu, Chien Yung-Jiun, Wu Meng-Yu, Chen Chih-Hao, Chang Chun-Yu
Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan.
School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Pharmaceuticals (Basel). 2022 Aug 11;15(8):989. doi: 10.3390/ph15080989.
Intraocular pressure (IOP) is crucial to the well-being of eyes. During anesthesia, the administration of succinylcholine and endotracheal intubation are associated with an increase in IOP, which may be attenuated by short-acting opioids. However, the drug of choice among the commonly used short-acting opioids is unclear. This study aimed to evaluate the effects of fentanyl, sufentanil, alfentanil, and remifentanil on IOP measured after the administration of succinylcholine and after endotracheal intubation in patients undergoing general anesthesia. Five databases were searched. Randomized controlled trials (RCTs) that compared short-acting opioids and reported at least one of the clinical outcomes of interest were included. Nine RCTs with 357 patients were included. Remifentanil (1 μg kg) more effectively alleviated the increase in IOP than the placebo after the administration of succinylcholine [mean difference (MD) of IOP, -3.64; confidence interval (CI), -5.47 to -1.81 and after endotracheal intubation (MD, -9.71; CI, -11.91 to -7.51). Remifentanil (1 μg kg) ranked the best in terms of both attenuating the increase in IOP after the administration of succinylcholine [surface under the cumulative ranking curve (SUCRA), 0.91; normalized entropy (NE), 0.47; and after endotracheal intubation (SUCRA, 0.89; NE, 0.54) among all of the treatments. Remifentanil (1 μg kg) should be considered the drug of choice in the circumstances where increased IOP is a great concern.
眼压(IOP)对眼睛的健康至关重要。在麻醉期间,琥珀酰胆碱的给药和气管插管与眼压升高有关,短效阿片类药物可能会减轻这种升高。然而,常用短效阿片类药物中哪种是首选药物尚不清楚。本研究旨在评估芬太尼、舒芬太尼、阿芬太尼和瑞芬太尼对全身麻醉患者给予琥珀酰胆碱后及气管插管后测量的眼压的影响。检索了五个数据库。纳入了比较短效阿片类药物并报告至少一项感兴趣的临床结局的随机对照试验(RCT)。纳入了9项RCT,共357例患者。给予琥珀酰胆碱后,瑞芬太尼(1μg/kg)比安慰剂更有效地减轻眼压升高[眼压的平均差值(MD),-3.64;置信区间(CI),-5.47至-1.81],气管插管后也是如此(MD,-9.7l;CI,-11.91至-7.51)。在所有治疗中,瑞芬太尼(1μg/kg)在减轻给予琥珀酰胆碱后眼压升高方面[累积排序曲线下面积(SUCRA),0.91;标准化熵(NE),0.47]以及气管插管后(SUCRA,0.89;NE,0.54)均排名最佳。在眼压升高是一个重大问题的情况下,应考虑将瑞芬太尼(1μg/kg)作为首选药物。